Examining the prevalence of prediabetes in pediatrics (VIDEO)

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Contemporary Pediatrics sits down exclusively with Philippe F. Backeljauw, MD, a pediatric endocrinologist to discuss the one key condition for which he believes community pediatricians should be especially aware-Turner syndrome.

With the new drug application accepted with priority review, the FDA has assigned a date of November 20, 2025, to complete its review for potential approval.

The decision makes hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) the only FDA-approved oral formulation of hydrocortisone.

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

Most want to start the conversation, but confidence and timing vary.